Interview: Q BioMed accelerates advances in vascular therapeutics

Feb 24, 2016 Tags: Biotech Business development Pharma

Ensuring that all the necessary resources are in place to build a sustainable business is a key challenge for most entrepreneurs. They need access to capital and expertise without having to give it away cheaply. Q BioMed Inc CEO Denis Corin explains to Mike Ward, global director of content for Informa’s pharma insight products, how his biomedical acceleration and development company is providing target companies and assets access to strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential.


The company is agnostic in terms of geography, therapeutic focus, or development phase. One of Q BioMed’s recent acquisitions was Mannin Research Inc., a biotech that is developing a new class of vascular therapeutics and led Dr. Susan E. Quaggin, chief of the division of nephrology and director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago. The primary target indication is for a first-in-class therapeutic eyedrop for the treatment of glaucoma in adults and children.

Interviewee: Denis Corin – CEO, Q BioMed Inc.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights